Source: NewMediaWire

Dom Gatto Appointed CEO of Solos Endoscopy Corp.

BOSTON, MA--(Marketwired - Jun 30, 2017) - Solos Endoscopy, Inc. (OTC PINK: SNDY), a provider of quality medical devices to hospitals and clinics across the country, has announced that the Board of Directors has appointed and engaged in a long term (5-year) employment agreement with Dom Gatto as the CEO and Chairman of the Board of Solos Endoscopy.

Mr. Gatto has a long relationship with Solos Endoscopy and previously sat on its Board of Directors. Mr. Gatto is the founder of AMG Development, a medical device consulting firm.

His professional experience includes many different areas ranging from product development to executive management for numerous start-up entities. He founded MedTrek, an innovative surgical company which partnered with Olympus worldwide. He was later Chief Operating Officer for start-up Acueity Healthcare, a revolutionary technology for early detection of breast cancer and the forerunner to Solos' MammoView product line. During his career, he has developed, launched and successfully managed over 75 medical devices ranging from polymer-based disposables to integrated imaging systems. He holds 7 patents and is co-inventor on three patent-pending medical devices.

"I look forward to the opportunity to bring Solos back to its prominent status within the medical device marketplace. As one of the pioneering endoscopic companies, its roots reach back to the beginning of the commercialization of endoscopic systems and tools. And we will look to capitalize on this rich history as we reposition the company for growth," stated Dom Gatto.

About Solos Endoscopy, Inc.:

Solos Endoscopy recently celebrated its 30th Year of providing quality innovative healthcare instruments to Hospitals across the United States. For more than 30 Years, from medical schools to hospitals, surgeons have relied on Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its line of products is available on the Company's website at:

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Contact Information:

Solos Endoscopy, Inc.
Investor Relations
(617) 360-9719